Before the advent of ICI, immunotherapy in the treatment of advanced melanoma consisted of the use of high-dose IL-2 and adoptive cell therapy with autologous tumor-infiltration lymphocytes, with ORR of about 15% and up to 50%, respectively [50,51,52,53]. Here, IL2 is linked to melanoma.